MX2024007066A - Uso de amivantamab para tratar el cancer colorrectal. - Google Patents
Uso de amivantamab para tratar el cancer colorrectal.Info
- Publication number
- MX2024007066A MX2024007066A MX2024007066A MX2024007066A MX2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A MX 2024007066 A MX2024007066 A MX 2024007066A
- Authority
- MX
- Mexico
- Prior art keywords
- colorectal cancer
- amivantamab
- antibody
- treat colorectal
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287557P | 2021-12-09 | 2021-12-09 | |
| US202163290765P | 2021-12-17 | 2021-12-17 | |
| PCT/IB2022/061991 WO2023105479A1 (en) | 2021-12-09 | 2022-12-09 | Use of amivantamab to treat colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007066A true MX2024007066A (es) | 2024-06-21 |
Family
ID=84537874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007066A MX2024007066A (es) | 2021-12-09 | 2022-12-09 | Uso de amivantamab para tratar el cancer colorrectal. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230183360A1 (https=) |
| EP (1) | EP4444426A1 (https=) |
| JP (1) | JP2025500784A (https=) |
| KR (1) | KR20240112963A (https=) |
| AU (1) | AU2022407875A1 (https=) |
| CA (1) | CA3241933A1 (https=) |
| IL (1) | IL313410A (https=) |
| MX (1) | MX2024007066A (https=) |
| WO (1) | WO2023105479A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547867A (zh) * | 2024-01-16 | 2025-12-16 | 美商健生生物科技公司 | 使用阿米維單抗治療結腸直腸癌 |
| WO2026022733A1 (en) * | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
| WO2026022739A1 (en) * | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| BR112021016149A2 (pt) * | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| JP7783182B2 (ja) * | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
-
2022
- 2022-12-08 US US18/077,318 patent/US20230183360A1/en not_active Abandoned
- 2022-12-09 MX MX2024007066A patent/MX2024007066A/es unknown
- 2022-12-09 KR KR1020247022472A patent/KR20240112963A/ko active Pending
- 2022-12-09 AU AU2022407875A patent/AU2022407875A1/en active Pending
- 2022-12-09 CA CA3241933A patent/CA3241933A1/en active Pending
- 2022-12-09 EP EP22826446.1A patent/EP4444426A1/en active Pending
- 2022-12-09 IL IL313410A patent/IL313410A/en unknown
- 2022-12-09 WO PCT/IB2022/061991 patent/WO2023105479A1/en not_active Ceased
- 2022-12-09 JP JP2024534144A patent/JP2025500784A/ja active Pending
-
2025
- 2025-01-17 US US19/028,911 patent/US20250257139A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250257139A1 (en) | 2025-08-14 |
| CA3241933A1 (en) | 2023-06-15 |
| JP2025500784A (ja) | 2025-01-15 |
| IL313410A (en) | 2024-08-01 |
| WO2023105479A1 (en) | 2023-06-15 |
| US20230183360A1 (en) | 2023-06-15 |
| KR20240112963A (ko) | 2024-07-19 |
| EP4444426A1 (en) | 2024-10-16 |
| AU2022407875A1 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007066A (es) | Uso de amivantamab para tratar el cancer colorrectal. | |
| CL2024001384A1 (es) | Moleculas de anticuerpo y conjugados | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| CL2022000495A1 (es) | Formulaciones farmacéuticas y regímenes de dosificación para proteínas de unión multiespecíficas que se unen a her2, nkg2d y cd16 para el tratamiento del cáncer | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| CY1117241T1 (el) | Αντισωματα anti-igf | |
| BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
| FI3665198T9 (fi) | EGFR:ää ja cMET:tä sitovia vasta-aineita | |
| MX358728B (es) | Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados. | |
| CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
| MX2010001757A (es) | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. | |
| MX2023001556A (es) | Anticuerpos que se dirigen a egfr y uso de los mismos. | |
| MX2019014316A (es) | Un nuevo anticuerpo anti-c-met y uso del mismo. | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
| MX2024012294A (es) | RECEPTORES DE TGF-ß Y MÉTODOS DE USO | |
| PE20221830A1 (es) | Anticuerpos especificos contra la claudina 18.2 tumoral | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| PE20221326A1 (es) | Anticuerpos anti-mertk y metodos de uso de los mismos | |
| PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
| CL2024002974A1 (es) | Anticuerpos monoclonales y anticuerpo biespecifico contra c-met | |
| MX2023002104A (es) | Composiciones y métodos para tratar cánceres positivos para egfr. | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| EA201491352A1 (ru) | Способ лечения рака груди | |
| MX2018001095A (es) | Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico. |